EUVIMEDOpdag EUVIMED
Open access

The pathogenic E139D mutation stabilizes a non‐canonical active state of the multi‐domain phosphatase SHP2

Anne E van Vlimmeren iD, Ziyuan Jiang, Deepti Karandur iD, Anya T Applebaum Licht, Neel H Shah iD

Protein Science · 2025

DOI: 10.1002/pro.70373 ↗

At a glance

Journal article in Protein Science, 2025. Written by Anne E van Vlimmeren and 4 co-authors. Institution: Department of Chemistry, Columbia University, New York, New York, USA. Major MEDLINE topics: Protein Tyrosine Phosphatase, Non-Receptor Type 11. Cited 2 times so far (Crossref); 38 references. The full text is freely available in PubMed Central. Funded by: National Science Foundation, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Dysregulation of the phosphatase SHP2 is implicated in various diseases, including congenital disorders and cancer. SHP2 contains two phosphotyrosine‐recognition domains (N‐SH2 and C‐SH2) and a protein tyrosine phosphatase (PTP) domain. The N‐SH2 domain is critical for SHP2 regulation. In the auto‐inhibited state, it binds to the PTP domain and blocks the active site, but phosphoprotein engagement destabilizes the N‐SH2/PTP domain interaction, thereby exposing the active site. Many disease mutations in SHP2 are at the N‐SH2/PTP interface, and they hyperactivate SHP2 by disrupting auto‐inhibitory interactions. The activating E139D mutation represents an exception to this mechanism, as it resides in the C‐SH2 domain and makes minimal interactions in auto‐inhibited and active state crystal structures. In this study, using AlphaFold2 modeling and molecular dynamics simulations, we identify an alternative active conformation of SHP2, in which Glu139 interacts with Arg4 and Arg5 on the N‐SH2 domain to stabilize a novel N‐SH2/C‐SH2 interface. Using double mutant cycles, we show that this active state is further stabilized by the E139D mutation. Finally, we demonstrate that the E139D mutation enforces an active conformation with distinct phosphoprotein binding preferences from canonical hyperactive mutants. Thus, our study reveals a novel mechanism for SHP2 dysregulation.

Subjects

MeSH terms (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11HumansMolecular Dynamics Simulationsrc Homology DomainsMutationModels, MolecularCatalytic Domain

Author keywords

AlphaFold2PTPN11conformational ensemblemolecular dynamicstyrosine phosphatase

Substances

Protein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, human

Authors and institutions

  • Department of Chemistry, Columbia University, New York, New York, USA.
  • Department of Biological Sciences, Columbia University, New York, New York, USA.
  • Independent Researcher, San Francisco, California, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA.

ORCID profiles: Anne E van Vlimmeren, Deepti Karandur, Neel H Shah

Funding

  • National Science Foundation
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Cite

APA

van Vlimmeren, A. E., Jiang, Z., Karandur, D., Applebaum Licht, A. T., & Shah, N. H. (2025). The pathogenic E139D mutation stabilizes a non‐canonical active state of the multi‐domain phosphatase SHP2. Protein Science. https://doi.org/10.1002/pro.70373

Vancouver

van Vlimmeren AE, Jiang Z, Karandur D, Applebaum Licht AT, Shah NH. The pathogenic E139D mutation stabilizes a non‐canonical active state of the multi‐domain phosphatase SHP2. Protein Science. 2025. doi:10.1002/pro.70373

BibTeX
@article{vanVlimmeren2025,
  author = {van Vlimmeren, Anne E and Jiang, Ziyuan and Karandur, Deepti and Applebaum Licht, Anya T and Shah, Neel H},
  title = {The pathogenic E139D mutation stabilizes a non‐canonical active state of the multi‐domain phosphatase SHP2},
  journal = {Protein Science},
  year = {2025},
  doi = {10.1002/pro.70373}
}
Start for free →